DCF Advisers, LLC
- SEC CIK
- 0001802493
- Latest filing
- Aug 10, 2026
ALNY holding history
Alnylam Pharmaceuticals, Inc. in every 13F filed by DCF Advisers, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ALNY overviewAll 13F holders of ALNYFull Q2 2026 holdings
- Shares (Q1 2024)
- 0
- Sold out in Q1 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2024 | 0 | $0 | 0.0% | −1,300−100.0% | Sold out | Holders |
| Q4 2023 | 1,300 | $248.8K | 0.2% | −500−27.8% | Reduced | Holders |
| Q3 2023 | 1,800 | $318.8K | 0.2% | +200+12.5% | Added | Holders |
| Q2 2023 | 1,600 | $303.9K | 0.2% | +200+14.3% | Added | Holders |
| Q1 2023 | 1,400 | $280.4K | 0.2% | 00.0% | Unchanged | Holders |
| Q4 2022 | 1,400 | $332.7K | 0.3% | 00.0% | Unchanged | Holders |
| Q3 2022 | 1,400 | $280.0K | 0.2% | −3,600−72.0% | Reduced | Holders |
| Q2 2022 | 5,000 | $729.0K | 0.5% | −14,000−73.7% | Reduced | Holders |
| Q1 2022 | 19,000 | $3.10M | 1.8% | +1,000+5.6% | Added | Holders |
| Q4 2021 | 18,000 | $3.05M | 1.5% | +500+2.9% | Added | Holders |
| Q3 2021 | 17,500 | $3.30M | 1.8% | 00.0% | Unchanged | Holders |
| Q2 2021 | 17,500 | $2.97M | 1.5% | −2,500−12.5% | Reduced | Holders |
| Q1 2021 | 20,000 | $2.82M | 1.4% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.